← Back to directory
O
OCCIDENT
Munich, GermanyWebsite ↗
OCCIDENT is an owner-managed venture capital firm that invests its own capital in deep tech startups, particularly spin-offs from scientific research, with the goal of bringing innovative and meaningful solutions to societal challenges. The firm acts as a long-term partner, providing financial support and entrepreneurial experience to its portfolio companies from early stages.
Last raised
Unknown
Latest fund size
—
AUM
—
Funds raised
Capital this firm has raised, newest first
No funds on record
Recent investments
Companies this firm has funded, newest first
| Company | Round | Amount | Date | Source |
|---|---|---|---|---|
| Immitra Bio | — | — | Unknown | occident.group ↗ |
| G-Metrics | Growth | — | Feb 2026 | pitchbook.com ↗ |
| Tubulis | Series C | $320M | Oct 2025 | occident.group ↗ |
| Lymphatica Medtech | Series B | $19.1M | Oct 2024 | occident.group ↗ |
| Hemotune | Series B | $15.7M | Mar 2024 | occident.group ↗ |
| AltavoLead | Series A | $5.3M | Feb 2024 | bmt-seed.com ↗ |
| EBAMed | Series A | $15.3M | Jun 2023 | occident.group ↗ |
| Resistell | Series B | $9.5M | Dec 2022 | startupticker.ch ↗ |
Sources
Where this data came from